Abstract | OBJECTIVE: MATERIAL AND METHODS: From June 2007 to March 2012, 60 patients with HBV-related advanced HCC, all receiving the same FMP chemotherapy protocol, were enrolled. Of them, 20 did not receive any antiviral therapy, whereas the remaining 40 patients (sex and age matched) received telbivudine preemptive therapy. RESULTS: Progressive decrease of aminotransferase levels (p < 0.05) and progressive increase of viral clearance rates (p < 0.001) were found in telbivudine-treated group. No drug resistance developed during the course of treatment. When compared with non- antiviral-treated patients, a significantly higher post-therapeutic estimated glomerular filtration rate (eGFR) was found in the telbivudine-treated group (p < 0.001). In patients with initial eGFR >100 ml/min (n = 34), the median overall survival was significantly longer in the telbivudine-treated group (12.1 vs. 4.9 months; p = 0.042). CONCLUSION: Preemptive use of telbivudine significantly prevented eGFR deterioration caused by cisplatin-based chemotherapy in HBV-related advanced HCC. In patients with initially sufficient eGFR level, telbivudine treatment was associated with a longer overall survival.
|
Authors | Chih-Lang Lin, Rong-Nan Chien, Charisse Yeh, Chao-Wei Hsu, Ming-Ling Chang, Yi-Cheng Chen, Chau-Ting Yeh |
Journal | Scandinavian journal of gastroenterology
(Scand J Gastroenterol)
Vol. 49
Issue 12
Pg. 1456-64
(Dec 2014)
ISSN: 1502-7708 [Electronic] England |
PMID | 25283499
(Publication Type: Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Antiviral Agents
- Protective Agents
- Telbivudine
- Mitomycin
- Cisplatin
- Fluorouracil
- Thymidine
|
Topics |
- Acute Kidney Injury
(chemically induced, prevention & control)
- Adult
- Aged
- Antineoplastic Agents
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Antiviral Agents
(therapeutic use)
- Carcinoma, Hepatocellular
(drug therapy, mortality, virology)
- Cisplatin
(adverse effects, therapeutic use)
- Female
- Fluorouracil
(adverse effects, therapeutic use)
- Hepatitis B, Chronic
(complications, drug therapy)
- Humans
- Kaplan-Meier Estimate
- Liver Neoplasms
(drug therapy, mortality, virology)
- Male
- Middle Aged
- Mitomycin
(adverse effects, therapeutic use)
- Protective Agents
(therapeutic use)
- Telbivudine
- Thymidine
(analogs & derivatives, therapeutic use)
- Treatment Outcome
|